SINAPPS2 Clincal Trial (open to recruitment)

We have found that a small proportion of people with early psychosis have anti-neuronal membrane antibodies in their blood. We have shown, in open label pilot studies, that eliminating these antibodies induces remission.

We are conducting a double-blinded randomised controlled trial (SINAPPS2) which aims to test the efficacy and safety of IVIG and Rituximab treatment versus placebo of patients with antibody-associated psychosis. During the trial, study participants will continue with standard psychiatric care including antipsychotic medication as prescribed by their psychiatrist.

Information for clinicians here.